In contrast, anorexigenic intestinal peptides as peptide YY (PYY), pancreatic polypeptide (PP), GLP-1, oxyntomodulin and cholecystokinin are low during the fasting period, and their level increases after a meal, and some of them are released proportionally to the amount of calories ingested (Reviewed in [127])
Its also FDA-approved for androgenetic alopecia (pattern hair loss), so if your GLP-1-related shedding unmasks underlying genetic hair loss, minoxidil addresses both conditions
We assume that most who use GLP-1 agonists do not modify diet/lifestyle to create better behaviors, however, I wonder if those on GLP-1 agonists could be clinically at risk of, or are malnourished
A patient in the clinical trial had a possible liver injury that was no longer a problem once they stopped taking that drug, Pfizer said
Most insurance plans will not cover semaglutide for weight loss, considering it a non-medical cosmetic treatment